BSG and prostate cancer: Eight trials [9,11,12,18,19,20,21,24] reported the difference of CD147 positivity rate between prostate cancer and benign prostatic hyperplasia, including 575 prostate cancer tissues and 291 benign prostatic hyperplasia tissues.